Our meta-analysis suggests that while anti-CD38 monoclonal antibodies may be associated with an increased risk of severe lymphopenia, neutropenic infections, and thrombocytopenia, they also offer improved clinical efficacy in MM treatment. Here, CD38 is linked to Thrombocytopenia.